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Tauopathies are neurodegenerative diseases defined by the pathological accumulation of filamentous tau in the central nervous system. Tau is a microtubule-associated protein predominantly expressed in the axonal compartment of neurons, where it promotes microtubule assembly and stabilization. Among tauopathies, the most frequent by far is Alzheimer's disease, followed by progressive supranuclear palsy, corticobasal degeneration and Pick's disease.
In these tauopathies, tau becomes abnormally phosphorylated, accumulates in the somato-dendritic compartment of neurons and aggregates into neurofibrillary tangles. The in vitro evidence that abnormally phosphorylated tau is less able to stabilize microtubules (Bramblett et al., 1993; Drechsel et al., 1992; Grundke-Iqbal et al., 1986; Iqbal et al., 1986) led to the formulation of the "tau-microtubule" hypothesis, which states that tau phosphorylation provokes microtubule breakdown, causing axonal transport impairment and subsequent synaptic dysfunction (Iqbal and Grundke-Iqbal, 1991; Lee and Trojanowski, 1992) . Studies in cellular models (Dayanandan et al., 1999; Lovestone et al., 1996) and in a drosophila model of tauopathy (Cowan et al., 2010; Mudher et al., 2004) have confirmed that tau phosphorylation can induce microtubule breakdown. An alternative hypothesis states that the overexpression of normal, non-phosphorylated tau can impair axonal trafficking by stearic hindrance of motors proteins, as shown in vitro (Dixit et al., 2008; Seitz et al., 2002; Vershinin et al., 2007) and in cells (Ebneth et al., 1998; LaPointe et al., 2009; Mandelkow et al., 2003; Stoothoff et al., 2009; Trinczek et al., 1999) ; tau phosphorylation being considered as a compensatory mechanism which aims at rescuing axonal transport (Falzone et al., 2009 (Falzone et al., , 2010 Vossel et al., 2010) . Regardless of the exact mechanism, both normal and hyperphosphorylated tau can aggregate and thereby impair axonal transport during the course of the disease. Importantly, axonopathy and transport deficits appear to occur early in the pathogenesis of AD and related mouse models (Stokin et al., 2005) .
These effects of pathological tau on axonal transport, as mentioned above, are described at the microscopic scale of individual axons either ex vivo or in vitro and using cell culture and drosophila model system. However, they may not be relevant at the macroscopic scale of fiber tracts. The complexity of neuronal networks, and the various interactions that exist between glial and neuronal cells, make one cautious when interpreting the results of single-axon studies and inferring their relevance to the mammalian brain. Hence, the effects of tauopathy on axonal transport need to be assessed at the macroscopic level using mammalian models. Only a few axonal transport studies have been conducted in mouse models of tauopathy, and their results have been contradictory. Two studies performed in transgenic mice expressing normal human tau showed either retarded (Ishihara et al., 1999) or normal axonal transport (Yuan et al., 2008) . Two additional reports using transgenic mice expressing mutant human tau found some evidence of impairment in axonal transport (Ittner et al., 2008; Zhang et al., 2004) , although one of those was limited to the transport of tau itself, and not organelles and cargo proteins (Zhang et al., 2004) . None of these studies established a quantitative correlation between the level of abnormal tau and the degree of axonal impairment. Indeed, there is still a need to prove in vivo that axonal transport deficits represent a significant event during the course of tauopathy.
The reason for the contradictory findings to date on axonal transport in mouse models of tauopathy may be related to the models employed, but also to the technical challenges of measuring axonal transport. These prior studies in mouse models required invasive techniques, such as a nerve ligation or injection into the spinal cord. Nerve ligation induces nerve injury and local ischemia, which may interfere with normal axonal transport (Ittner et al., 2008; Zhang et al., 2004) . Injection of radiolabeled amino acids requires deep surgical procedures which can also induce ischemic-hemorrhagic changes in the area of interest (Zhang et al., 2004 (Zhang et al., , 2005 . Both these techniques rely on a post-mortem quantification of the transported cargoes, and thus can only evaluate transport mechanisms at a single time point for each animal. Lastly and importantly, these transport measurements have always been done in the axonal compartment, as it is technically easier to access than the dendritic trees. However, it is well known that pathological tau accumulation takes place in the somato-dendritic compartment of neurons (Lee et al., 2001) . Hence, the ideal approach for the study of active transport in mouse models of tauopathy would provide a non-invasive, longitudinal quantification of transport in all neuronal compartments (i.e. soma, dendrites and axons), thus giving a comprehensive, 4D picture of neuronal transport in fiber tracts.
Manganese-enhanced MRI (MEMRI) is a non-invasive imaging technique based on the physicochemical properties of manganese. As a calcium-analogue, manganese enters neurons via Ca 2+ channels (Drapeau and Nachshen, 1984; Lu et al., 2007; Narita et al., 1990; Sloot and Gramsbergen, 1994) , is transported along the microtubule system by active transport partially dependent on kinesin (Bearer et al., 2007a; Sloot and Gramsbergen, 1994; Smith et al., 2007; Takeda et al., 1998b) , is released at the synaptic cleft (Takeda et al., 1998b) , and is taken up by the post-synaptic neuron (Saleem et al., 2002; Takeda et al., 1998a; Tjalve et al., 1995 Tjalve et al., , 1996 . Thanks to its paramagnetic properties, manganese causes a local increase of MR signal intensity in neurons that can be detected on T1-weighted images (Lin and Koretsky, 1997) . Hence, by repeated MR examinations over time, the displacement of manganese in neurons can be dynamically monitored (Pautler and Koretsky, 2002; Pautler et al., 1998) . For these reasons, MEMRI can be used as a non-invasive in vivo tool to study neuronal transport in animal models, either in the visual system using intraocular injection of manganese (Bearer et al., 2007a) , in the olfactory system using intranasal delivery of manganese (Cross et al., 2008; Smith et al., 2007) , in deep fiber systems using intracerebral injection of manganese (Bearer et al., 2007b) , or in peripheral nerves following topical injection of manganese. (Matsuda et al., 2010) . MEMRI studies of the olfactory system have reported an in vivo impairment of axonal transport in transgenic mouse model of amyloid β deposition (Massaad et al., 2010; Smith et al., 2007 Smith et al., , 2010a and in a triple transgenic mouse model with both amyloid β deposition and neurofibrillary tangles (Kim et al., 2011) . One MEMRI study of the olfactory system focusing on the interaction between APP and tau included a subgroup of animals expressing human mutated tau. Results from this subgroup suggested an in vivo impairment of axonal transport related to tauopathy. However this study did not comprise any assessment of pathological tau in the brain of the animals (Smith et al., 2010b) . Our goal was to examine by MEMRI a mouse model of tauopathy to address the following questions:
-Can we detect in vivo an effect of mutant human tau on neuronal transport? -Can we correlate these alterations of neuronal transport with the degree of tauopathy, thus providing a functional biomarker of pathological tau in mice?
Material and methods

Animals
Imaging experiments were performed on homozygous JNPL3 transgenic mice (Taconic; (Lewis et al., 2000) ) and wild-type (WT) control mice of the same strain background. (C57BL/6, DBA/2 and SW mixed background). In this homozygous model, tau pathology becomes evident around 2-3 months of age and is severe at 9 months (Asuni et al., 2007) . 25 animals (13 Tg and 12 WT) were imaged and monitored longitudinally at 3, 6 and 9 months of age. To examine if there was a correlation between the extent of tauopathy and changes in axonal transport, mice were euthanized and sacrificed at each of the selected time points: 8 animals (4 Tg and 4 WT) after the 3-month old examination, 10 animals (5 Tg and 5 WT) after the 6-month old examination, and 7 animals (4 Tg and 3 WT) after the 9-month old examination. In addition, to control for possible confounding effects related to the potentially cumulative neurotoxicity of manganese, a supplementary group of 10 mice (5 Tg and 5 WT) was examined at 9 months only and then euthanized. Each group of mice included comparable number of males and females. A total of 35 animals were used for the study. Procedures were performed in accordance with the Institutional Animal Care and Use Committee at the New York University School of Medicine.
MnCl 2 administration and MR scanning
MnCl 2 (1.5 μL of 5 M MnCl 2 ) was administered under anesthesia (5% isoflurane) into one nostril of the mouse using a micropipette under microscopic control. Mice were maintained under anesthesia for 1 min after the Mn administration, in order to delay the cough reflex and to ensure a correct penetration of Mn in the nasal epithelium. Still, cough reflex did occur in most of the animals after the anesthesia, and may have caused some variation in the exact volume of manganese delivered; however, these random variations were equally likely to occur in both WT and Tg animals. After the instillation, each mouse was allowed to recover for a few minutes on a heating pad, and was then transferred to its cage.
During each imaging time course set, mice were scanned 9 times: once before manganese injection, 7 times during the 2 days following the injection (at 1, 4, 8, 12, 24, 36 and 48 h after injection), and finally 7-10 days after the injection. MRI scans were performed on a 7 T micro-MRI system, consisting of a 200-mm horizontal bore magnet (Magnex Scientific, UK) with an actively shielded gradient coil insert (Bruker BGA-9S; ID 90-mm, 750-mT/m gradient strength, 100-μs rise time). The same in-house birdcage quadrature coil was used for all image acquisitions (ID = 22 mm, length 29 mm). Each scan consisted of a 3D T1-SPGR sequence with the following parameters: FOV = 19.2 × 19.2 × 9.6 mm, matrix size = 128 × 128 × 64, spatial resolution = (150 μm) 3 , TR/TE = 15/4 ms, averages = 6, acquisition time = 15 min. Flip angle (18º) was chosen to provide the greatest T1-enhancement contrast (Neelavalli and Haacke, 2007) . Ten minutes before MR imaging, each mouse was anesthetized with 5% isoflurane, and then placed in an in-house holder system including a tooth bar, in order to maintain the head in a reproducible and stationary position in the coil. During MR imaging, each mouse was kept under anesthesia using isoflurane in air (1-2%), its body temperature being maintained at 35-37°C with a heated waterbed, and its respiratory rate being constantly monitored. The level of isoflurane was continuously adjusted so that the respiratory rate was always between 40 and 60 per minute. After MR imaging, each mouse was allowed to recover on a heating pad for a few minutes, and was then transferred back to its cage until the next scan. The total time under anesthesia for each mouse did not exceed 30 min per scan.
MR image processing
All the MR datasets were processed using the ImageJ software (NIH, Rockville, MD). A rigid registration was systematically performed between the MRI datasets acquired serially from each individual mouse at 9 different time points using an automatic registration with the Rigid_Registration.jar plugin (J Schindelin, M Longair). Unlike inter-subject registration, the intra-subject realignment assessed for the set of 9 images time points proved effective since it is less prone to anatomical mis-registration minimizing translation requirement. Four regions of interest (ROI) were defined on the following structures using a mouse brain atlas: the glomerular layer, the mitral cell layer, the anterior part of the piriform cortex, and the pons; the latter was used to normalize signal intensities at each time point (see Supplementary Fig.  8 ). The contralateral side was not used for normalization as some degree of enhancement was observed in about half of the animals in similar proportion in both Tg and WT groups.
For each mouse, the normalized signal intensities in each ROI were plotted and fitted to a previously described tract-tracing bolus model (Cross et al., 2008) using an in-house Matlab fitting routine (The Mathworks 2009). Briefly, the manganese transport was assumed to follow a drift/diffusion model described by the one-dimensional Fokker-Planck equation (van Kampen, 1981) . The parameters defining the time-intensity curves acquired experimentally were extracted using a nonlinear least square fitting based on the LevenbergMarquardt algorithm. For each mouse, the parameter of global scaling, reflective of the initial neuronal uptake of manganese, was estimated by fitting in only the glomerular layer ROI, which was the closest ROI to the site of infusion; the same value was subsequently used in the two downstream ROI (mitral cell layer and anterior piriform cortex). The fitting process allowed us to determine the curve profile of normalized signal intensity changes in each ROI as a function of time, which reflects the local variations in manganese concentration over time (Wood and Hardy, 1993) . From the fitted curves, we extracted the following parameters: value of the peak of intensity (Pv), time-to-peak of intensity (Pt), and maximal value of the ascending slope (Sv).
Histology
These procedures were performed as previously described in detail (Sigurdsson, 2005) . Briefly, following MR examinations, the animals were terminally anesthetized with ketamine and xylazine (300 mg/kg ketamine + 60 mg/kg xylazine i.p.) and perfused transaortically with phosphate buffered saline. The right half of the brains, including right olfactory bulbs, were used for this study and were immersion fixed overnight in 2% periodate-lysineparaformaldehyde solution (PLP), and subsequently placed in 2% DMSO/20% glycerol in phosphate-buffered saline (PBS) overnight or until sectioned. Serial coronal sections (40 μm) were cut in a cryostat, and four series of every tenth section were used for staining. Sections were stored at − 30°C in an ethylene glycol cryoprotectant until used for histology.
Immunohistochemistry was performed as previously described (Sigurdsson, 2005) . Briefly, following several washes in PBS, freefloating sections were incubated in 0.3% H 2 O 2 for 15 min to block endogenous peroxidase activity, and then placed in a blocking solution for 1 h at room temperature, to block nonspecific binding. The blocking solution consisted of: 1) 5% milk in TBS (PHF1); 2) A mouse-on-mouse (MOM) blocking reagent from the MOM immunodetection kit (Vector Laboratories, Burlingame, CA; MC1); 3) A polyclonal antibody diluent solution with 2% bovine serum albumin and 10% goat serum (GFAP). The sections were then incubated overnight in the primary antibodies (see below Antibodies for immunohistochemistry). The biotinylated IgG secondary antibody and the avidin and peroxidase solutions (anti-mouse or anti-rabbit antibody, Vector Laboratories, Elite Kits, Burlingame, CA) were used at a 1:1000 dilution. Antibody staining was revealed with 3,3′-diaminobenzidine tetrahydrochloride (Sigma) with nickel ammonium sulfate (Mallinckrodt, Paris, KY) intensification. The sections were then mounted onto slides, air-dried, dehydrated and defatted, cleared in CitriSolv (Fisher Scientific), and cover slipped with Depex mounting media.
For neuronal counting, sections were stained with cresyl violet. Sections were first mounted onto slides, air-dried, defatted, progressively rehydrated and stained for 75 s in a solution of 0.1% cresyl violet (Sigma) in 0.01 M acetic acid, then dehydrated, cleared in CitriSolv (Fisher Scientific), and cover slipped with Depex mounting media.
Antibodies for immunohistochemistry
PHF1 and MC1 monoclonal antibodies (kindly provided by Dr. Peter Davies) were used at 1:2500 (PHF1) or 1:50 (MC1) dilution. PHF1 IgG1 antibody recognizes phosphorylated serine 396 and 404 located outside the microtubule-binding repeat on the C terminal of the tau protein (Otvos et al., 1994) . MC1 antibody is a conformation dependent IgG1 antibody that is similar to Alz-50 (IgM). Its reactivity depends on both the N terminus (amino acids 7-9), and an amino acid sequence of tau (amino acids 313-322) in the third microtubule binding domain that is both necessary and sufficient for in vitro formation of filamentous aggregates of tau similar to those seen in AD. However the pathological conformation of tau recognized by MC1 seems to precede the aggregation of tau into filaments and the resultant neurofibrillary degeneration (Jicha et al., 1999) . Both antibodies recognize tau pathology in the JNPL3 mouse model (Lewis et al., 2000) . GFAP polyclonal antibody (Dako, Glostrup, Denmark) was used at 1:1000. GFAP antibody recognizes the glial fibrillary acidic protein, a 50 kDa intracytoplasmic filamentous protein that constitutes a portion of the cytoskeleton in astrocytes, and has been shown to be the most specific marker for cells of astrocytic origin (Eng et al., 2000) .
Quantification of MC1, PHF1 and GFAP staining
In order to correlate MEMRI parameters with the expression of mutant human tau, we quantified the level of staining in 3 areas ( Fig. 1): 1) The mitral cell layer, which corresponds to our second ROI on MR images and contains the cell bodies of mitral cells; 2) The external plexiform layer, which is located just upstream of the mitral cell layer and contains the dendritic processes of mitral cells, and 3) The anterior piriform cortex, which corresponds to our third ROI on MR images, and contains cell bodies and axonal/dendritic processes of cortical neurons. In the glomerular layer, which was our first ROI on MR images, the degree of staining was not accurately quantifiable because of high level of non-specific staining at the edges of the olfactory bulb.
Quantitative analysis of tissue sections was performed using the ImageJ software (NIH, Rockville, MD). Six sections were analyzed per animal and per antibody stain (PHF1, MC1, GFAP), every 2 sections corresponding to each ROI (external plexiform layer, mitral cell layer, anterior piriform cortex). After digitization, sections were analyzed based on the same rectangular ROI manually placed within the layer of interest. A segmentation threshold was visually established to accurately identify staining in these areas. The measurement consisted of the fractional stained area in each ROI at 200× magnification (20× objective).
Cell counting
Cell counting was first performed in all ROI using a semi-quantitative method, by a visual ranking of cell density on a score of 1 to 4. Subsequently, unbiased neuronal counting was performed in the mitral cell layer of all animals. The mitral cell layer was chosen because of its easy delineation on coronal sections, which allows for cell counting in the whole layer. We used stereological image analysis software (StereoInvestigator 10, MicroBrightField Bioscience, Williston, VT) controlling a Ludl motorized stage in a Leica DM5000B microscope. The edges of the mitral cell layer were traced at low (200× magnification, 20× objective) and counting frames of 225 μm 2 were selected at random on a sampling grid by the image analysis software. Twelve to twenty counting frames were used on each section, representing 5% of the total area of the mitral cell layer visible on the corresponding section. Neurons were counted through a 100× objective with the optical fractionator method. Three to four sections per animal were analyzed. Final estimated cell counts in the mitral cell layer were expressed as number of neurons per mm 3 .
Statistical analysis
All the data were analyzed with GraphPad (San Diego, CA) Prism 5.0. Functional parameters of manganese propagation extracted from fitted MRI data (Pv, Pt, Sv), immunoreactivity on brain sections and cell density in the mitral cell layer were compared by two-tailed t test, either unpaired (comparing WT and Tg at the same age) or paired (comparing same animals at 3 and 6 months of age), except when the data failed at least two of the three normality tests (D'Agostino and Pearson, Shapiro-Wilk and Kolmogorov-Smirnov normality tests) or the F test to compare variances. In these cases data were compared using Mann-Whitney test (comparing WT and Tg at the at the same age) or the Wilcoxon signed rank test (comparing same animals at 3 and 6 months of age). Correlations between functional parameters of manganese propagation and tau pathology were assessed by Pearson correlation coefficient, except when the data failed at least two of the three normality tests or the test of equal variances, in these cases correlations were assessed using the non-parametric Spearman correlation coefficient. Due to typical variations in the degree of tau pathology observed in this mouse model between age-matched Tg animals, we considered only the 17 animals that were imaged both at 3 and 6 months of age for the analysis of the functional parameters defining the manganese propagation (Pv, Pt, Sv).
Results
MEMRI detects an age-related impairment of manganese propagation in the olfactory system of JNPL3 tauopathy mice
Curve profiles of normalized signal intensities, reflective of manganese propagation, were similar between WT and Tg at 3 months of age, but showed marked differences at 6 months of age, for both the glomerular layer ( Figs. 2A and B ) and the mitral cell layer (Figs. 3A  and B) . The fitting process performed in each mouse allowed us to . On this T1-weighted sequence performed 8 h after nasal manganese injection, the areas of increased signal intensity (white color) correspond to the anatomical regions in which Mn propagates along the olfactory tract and accumulates transiently in high concentration (Pautler et al., 1998) . The glomerular layer and the mitral cell layer both appear as hyperintensity separated by a narrow hypointense rim. analyze 3 parameters: the value of the peak of signal intensity (Pv), the time-to-peak of signal intensity (Pt), and the maximal value of the ascending slope of signal intensity (Sv) (Figs. 2 and 3C-E) . In our first ROI, the glomerular layer, all 3 parameters were significantly altered in Tg animals between 3 and 6 months of age: Pv was decreased, Sv was decreased and Pt was delayed (Figs. 2C-E) . In our second ROI, the mitral cell layer, curve profiles were globally lower than in the glomerular layer, but the same significant phenomena was observed (Figs. 3C-E) . In our third ROI, the piriform cortex, curve profiles were even lower, and significant differences were not obtained neither when comparing age, nor when comparing Tg vs. WT mice (data not shown).
Manganese transport dynamics, reflective of neuronal transport, correlates with the degree of tau pathology in the olfactory system of JNPL3 tauopathy mice
We compared the observed modifications in MEMRI parameters (Pv, Pt and Sv) with the degree of tau pathology in the corresponding neurons. Tau pathology could not be reliably quantified in the glomerular layer because of high levels of non-specific staining within this region; thus, we focused for this analysis on the mitral cells. The degree of staining was assessed in the external plexiform layer, which corresponds to the dendritic compartment of mitral cells, and in the "mitral cell layer" proper, which corresponds to the somatic compartment of mitral cells (Fig. 4, and Supplementary Figs. 9A-H) . In both compartments, MC1 and PHF1 immunoreactivity (IR) were higher in the Tg animals than in WT controls. PHF1 IR did not differ as robustly as MC1 IR, likely because of a moderate PHF1 IR in WT animals (Figs. 4B and D, p b 0.05) .
The peak of signal intensity (Pv) was the MEMRI parameter that demonstrated the strongest correlation with the degree of tauopathy (Figs. 5A-D) . Pv correlated significantly with the level of somatic PHF1 and MC1 IR (Figs. 5A and B, r = − 0.38, p b 0.05 and r = − 0.46, p b 0.01 respectively), and even more strongly with the level of dendritic PHF1 and MC1 IR (Figs. 5C and D, r = − 0.5, p b 0.005 for both). A threshold of 1.85 for the peak value allowed the separation of all Tg animals with MC1-positive dendrites (stained area >0.5%), from all Tg animals with low levels of MC1 dendritic staining (stained area b0.1%) and all except one WT animal (Fig. 5D) . When considering only the group of Tg animals, correlations were not significant between Pv and somatic PHF1 staining, dendritic PHF1 staining or somatic MC1 staining, but was highly significant between Pv and dendritic MC1 staining (r = − 0.78, p = 0.0002).
Among the two other parameters (Sv and Pt), only Sv showed a significant correlation with the level of somatic and dendritic MC1 IR (r = − 0.44, p b 0.01 and r = − 0.45, p b 0.01 respectively). The correlation of Sv with dendritic MC1 IR remained significant when considering the group of Tg animals only (r = − 0.50, p b 0.05, data not shown). Fig. 2 . Curve profiles of Mn transport in the glomerular layer were similar between Tg and WT at 3 months of age (A), but showed marked differences at 6 months of age (B) (raw data are presented as inserts to depict the mean and standard deviation of all the subjects considered in the fit). The fitting process enabled the extraction of curve parameters (i.e., peak value, maximal slope and time-to peak) in each animal. Curve parameters of 6 month-old Tg animals were significantly different from those of same animals at 3 months of age (C, D and E), and from those of age-matched WT (C). Mean value is represented for each group, with the standard error of the mean.
WT and Tg JNPL3 tauopathy mice did not differ in the number of glial cells and neurons in the olfactory system, further supporting that the observed differences in Mn dynamics are caused by perturbations in neuronal transport
It is well-known that in addition to its transport in neurons, manganese can also be stored in astrocytes (Aschner et al., 1999; Chan et al., 2008) . Thus, we quantified the degree of GFAP staining in the olfactory bulbs of Tg and WT animals to rule out confounding influence of astrogliosis in the Tg group. GFAP staining was comparable between WT and Tg animal at all ages, both in the external plexiform layer and in the mitral cell layer (Figs. 6A and B, .
Another potentially confounding variable to consider is a possible neuronal loss in the olfactory system of the tauopathy animals. To investigate this, we performed a semi-quantitative evaluation of neuronal density in the olfactory system of Tg and WT animals, by visual ranking. No significant difference was observed between Tg and WT in neuronal density within the glomerular layer, the mitral cell layer and the anterior piriform cortex at 3 and 6 month-old (data not shown). To definitely rule out neuronal loss in Tg animals, we performed an unbiased stereological quantification of neurons in the mitral cell layer of all animals. The average number of neurons per mm 3 did not differ significantly between 3 and 6 month-old Tg mice, nor between 6 month-old Tg mice and age-matched WT (Figs. 6C, and Supplementary Fig. 9M -P).
Comparison of animals that underwent one single examination at 9 months of age, and those that were examined at 3, 6 and 9 months of age, suggests that the amount of administered manganese was not neurotoxic
We did not observe significant difference in MEMRI parameters (Pv, Pt and Sv) or in histological characteristics (MC1, PHF1 and GFAP staining, neuronal density) between the subgroup of 9 month-old animals which were examined only once, and the subgroup of 9 month-old animals that were examined repeatedly at 3, 6 and 9 months of age, thus receiving three times more manganese (Fig. 7) .
Discussion
This in vivo study demonstrates an impairment of manganese propagation within the olfactory system between Tg and JNPL3 mice. Manganese propagation has been shown in the literature to be dependent on active axonal transport (Bearer et al., 2007a; Sloot and Gramsbergen, 1994; Smith et al., 2007; Takeda et al., 1998b) . In pathological conditions, other phenomenon such as neuronal loss or gliosis could also impair neuronal transport, but we showed that these were absent between Tg and JNPL3 mice we studied as compared to controls. Lastly, the significant correlations between manganese propagation parameters and levels of tauopathy in neurons assessed by immunohistochemistry strongly support the fact that manganese transport reflects active neuronal transport in our study. Thus, our results demonstrate for the first time an in vivo impairment Fig. 3 . Curve profiles of Mn transport in the mitral cell layer were similar between Tg and WT at 3 months of age (A), but showed marked differences at 6 months of age (B) (raw data are presented as inserts including the mean and standard deviation of all the subjects considered in the fit). Curve parameters of 6 month-old Tg animals were significantly different from those of same animals at 3 months of age (C, D and E), and from those of age-matched WT (C and D). Mean value is represented for each group, with the standard error of the mean. of neuronal transport related to the expression of mutant human tau in JNPL3 mice. Our results are in agreement with previous studies obtained in other transgenic animal models of tauopathy, expressing R406W (Zhang et al., 2004) and K369I (Ittner et al., 2008 ) mutant human tau, in which invasive techniques were used to quantify axonal transport in spinal cord and peripheral nerves. Significantly, our protocol provides a non-invasive estimation of neuronal transport in the mouse brain, thus being more relevant for the study of tauopathies. Using a long time-frame MEMRI protocol, we were able to acquire serial 3D data set with 150 μm isotropic spatial resolution and estimate the entire curve profile of manganese transport. This enabled us to calculate retrospectively different parameters of transport (i.e. peak value, maximal slope and time-to-peak) in any desired pixels within the olfactory tract in which manganese propagates. Although the physical meaning of each parameter remains to be studied further, these measurements are very useful. The peak value gave the highest statistical significance for the comparison of WT and Tg animals (Figs. 2C and 3C ), whereas the maximal slope was the best parameter to monitor Tg mice during aging (Figs. 2D and 3D ). These differences highlight the advantages afforded by the acquisition of the long time-frame protocol we used, which gives access to all parameters of manganese transport (Cross et al., 2008) . In contrast, short time-frame protocols are more widely used in mice, less time-consuming, and do not require any image registration; but they are limited to the analysis of an anatomical region predefined experimentally using a single parameter, the slope of manganese progression (Kim et al., 2011; Massaad et al., 2010; Smith et al., 2007 Smith et al., , 2010a . Moreover, during short-time frame protocols, neuronal transport is studied during the acquisition of MR images, i.e. when the mouse is still and anesthetized. In contrast, long time-frame protocols spanning over multiple sessions enable the overall displacement of manganese to occur in-between MR acquisitions while mice are fully awake and active within their usual environment; hence this allows the characterization of manganese transport under near physiological conditions.
In this study, we were able for the first time to correlate MEMRI parameters of neuronal transport (i.e. peak value and maximal slope) with a histological hallmark of a neurological disease, namely tau aggregates in neurons. Thus, our non invasive, in vivo and 4D approach provides a set of functional biomarkers of tauopathy in transgenic mice. Predictably, this correlation was stronger when looking at the degree of pathological tau in the dendrites of neurons, than in the soma of neurons, as neuronal transport occurs mainly in dendrites and axons. PHF1 staining did not correlate as well as MC1 staining with the MEMRI measurements, which is likely related to PHF1 reactivity in normal tissue.
The strong correlation we obtained between MEMRI parameters and tau pathology in the dendritic compartment stresses the importance of transport alterations occurring in dendrites, which has not been investigated so far in tauopathies, as all studies have focused on the axonal compartment of neurons. Indeed, the dendritic compartment is challenging to explore even with videomicroscopy, because of the extreme tortuosity of dendritic branches as compared to the linearity of axons. Thus, MEMRI provides a unique tool for the exploration of neuronal transport at a global level, occurring from dendrites to axons.
The MEMRI technique we describe could be very useful for preclinical evaluation of new therapies against AD and related tauopathies: MEMRI could assess the functional benefit of therapeutic strategies for clearing pathological tau and/or for restoring a normal neuronal function. In this regard, the set of preclinical functional biomarkers we have described may be very useful for selecting efficient drugs against various neurodegenerative diseases such as tauopathies.
Supplementary data to this article can be found online at http:// dx.doi.org/10.1016/j.neuroimage.2012.08.065. Fig. 5 . Peak value measured in the mitral cell layer correlated significantly with tau pathology (MC1 and PHF1 antibodies). Statistical significance was higher when considering dendritic tau (C and D) than somatic tau (A and B). A threshold of 1.85 for the peak value allowed the separation of all Tg animals with MC1-positive dendrites (stained area >0.5%), from all Tg animals with low levels of MC1 dendritic staining (stained area b0.1%) and all except one WT animal (Fig. 5D ). 
